Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

Dealmaking is in style again under President Donald Trump. Potential takeover targets include C3.ai, Viking Therapeutics, and ...

Revenue (GAAP) surged to $31.7 million, exceeding analysts’ expectations by 88.8% driven by strong ZURZUVAE growth. Net loss (GAAP) narrowed to $49.7 million. This revenue surge, exceeding analysts’ ...

US biotech major Biogen (Nasdaq: BIIB) reported a 7% rise in its second quarter revenue Friday, with sales of $2.45 billion.

The better-than-expected launch of a rare heart disease drug pushed Alnylam (Nasdaq: ALNY) past the $50 billion market ...

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.